Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis

Published:2021-06 Issue:6 Volume:27 Page:743-752
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Yu Justin S¹,Carlton Rashad²,Agashivala Neetu¹,Hassan Tarek³,Wykoff Charles C⁴

Affiliation:

1. Novartis Pharmaceuticals Corporation, East Hanover, NJ.

2. Xcenda LLC, Palm Harbor, FL.

3. Oakland University William Beaumont School of Medicine and Associated Retinal Consultants, Royal Oak, MI.

4. Retina Consultants of Houston, Retina Consultants of America, and Blanton Eye Institute and Houston Methodist Hospital, Houston, TX.

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Economic Assessment in Resource-Constrained Systems: Individual-Level Simulation Model in Wet Age-Related Macular Degeneration and Diabetic Macular Oedema;Ophthalmology and Therapy;2024-08-06

2. Efficacy and safety of Brolucizumab for neovascular age-related macular degeneration: a systematic review and meta-analysis;PeerJ;2024-06-21

3. Real-world experience with brolucizumab in neovascular age-related macular degeneration over 2 years: the REBA extension study;Graefe's Archive for Clinical and Experimental Ophthalmology;2023-12-08

4. Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment—A Meta-Analysis and Systematic Review;Journal of Clinical Medicine;2023-07-14

5. Antiangiogenic therapy for ocular diseases: Current status and challenges;MedComm – Future Medicine;2023-02-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3